Categories

OSCO’s recent presentation of the Official Review of the San Antonio Breast Cancer Symposium provided attendees with excellent updates on many breast cancer topics.  The first session was presented by Joyce O’Shaughnessy, MD on HR+ Breast Cancer.  The second session was a Radiation Oncology Update presented by Danushka Seneviratne, MD, PhD.  After a short break […]

The following information is available for State Society review:  §  Full Prescribing Information Including Boxed Warning and Medication Guide 

Merck announces new treatment indication for KEYTRUDA® Adjuvant Treatment Following Resection and Platinum-Based Chemotherapy for Adult Patients With Stage IB (T2a ≥4 cm), II, or IIIA NSCLC KEYTRUDA® (pembrolizumab) Injection 100 mg, as a single agent, is indicated for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 cm), […]

Pharmacyclics LLC, invites you to attend a Multidisciplinary Discussion during the 2022 ASH Annual Meeting on Incorporating Imbruvica® (ibrutinib) into treatment strategies.   The program will be held on Monday December 12th from 8:00 to 9:00 AM in Exhibit Hall/Theater 7 during the ASH Annual Meeting.  Session sponsored by Pharmacyclics LLC, an AbbVie company and […]

AstraZeneca recently announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki) is now approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti–HER2-based regimen either: in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.1 ENHERTU has Boxed […]

The Oklahoma Society of Clinical Oncology, Inc. would like to invite you to attend our 2022 Spring meeting. Join your colleagues to hear highlights from this state-of-the art symposium on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease. The “Best of” SABCS is an officially licensed program of the San Antonio […]

Merck announces that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.  •  PD-L1 diagnostic testing is not required prior to initiating treatment with KEYTRUDA in these patients.  Before prescribing KEYTRUDA® (pembrolizumab), please read the Prescribing Information. The Medication […]

KEYTRUDA® (pembrolizumab) is indicated for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. SELECTED SAFETY INFORMATION Severe and Fatal Immune-Mediated Adverse Reactions •  KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to […]

October 22, 2021     Subject: Voluntary withdrawal of PEPAXTO® (melphalan flufenamide) for the treatment of relapsed or refractory multiple myeloma   Dear Healthcare Provider:  This letter is to inform you about important information regarding PEPAXTO in the United States.  On October 22, 2021, Oncopeptides announced the decision to voluntarily withdraw the US accelerated approval for […]

Pfizer Vaccines US Medical Affairs will be hosting Immunization Site Training Sessions for All Providers on the Storage, Handling, & Administration for Current & Potential New Formulations of our COVID-19 vaccine (with our partner BioNTech). These sessions will be updated to reflect new information and changes that evolve.  Such updates will be identified at the start of each session and further explained […]